---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-056481"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:20:50.237522+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cryoport reports Q1 revenue of $52.3M, net loss $15.4M; FY2022 revenue guidance $260-265M

## Summary
- Revenue $52.3M, down 2% YoY; net loss to common holders $15.4M ($0.31 loss per share) vs loss of $5.7M ($0.13) in Q1 2021.
- Adjusted EBITDA $1.8M vs $7.2M in prior year; gross margin 42.7% vs 46.1%, impacted by $9.4M fire loss at New Prague plant.
- Biopharma/Pharma revenue $43.0M (+1%); Animal Health $6.8M (-24%); Reproductive Medicine $2.5M (+32%). Commercial therapy revenue grew 53.5% to $3.9M.
- Full-year 2022 revenue guidance $260-265M (17-19% growth). Cash and short-term investments $600M.
- Record 609 clinical trials supported, 81 in Phase 3 (up from 69). Board authorized $100M share repurchase; 306,300 shares repurchased for $8.3M.

## SEC filing metadata
- accession: 0001104659-22-056481
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465922056481/0001104659-22-056481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465922056481/tm2214645d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-056481
- JSON: https://secwatch.observer/filing/0001104659-22-056481.json
- Plain text: https://secwatch.observer/filing/0001104659-22-056481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.